Characteristics of patients enrolled in the study
| Category/characteristics . | Cohort 1 (N = 1584), n (%) . | Cohort 2 (N = 669), n (%) . | Cohort with sST2 level measurements (N = 756), n (%) . |
|---|---|---|---|
| Recipient age, y | |||
| ≥40 | 1132 (71) | 481 (72) | 532 (70) |
| <40 | 452 (29) | 188 (28) | 224 (30) |
| Donor age, ya | |||
| ≥30 | 963 (61) | 347 (52) | 392 (52) |
| <30 | 621 (39) | 322 (48) | 364 (48) |
| Recipient sex | |||
| Female | 723 (46) | 303 (45) | 340 (45) |
| Male | 861 (54) | 366 (55) | 416 (55) |
| Donor sex | |||
| Female | 498 (31) | 181 (27) | 198 (26) |
| Male | 1086 (69) | 488 (73) | 558 (74) |
| Blood mismatch | |||
| No type mismatch | 674 (43) | 293 (44) | 332 (44) |
| Donor–recipient mismatch | 910 (57) | 376 (56) | 424 (56) |
| Anti-thymocyte globulin/alemtuzumab prophylaxis* | |||
| No | 1074 (68) | 396 (59) | 477 (63) |
| Yes | 407 (26) | 273 (41) | 277 (37) |
| Missing | 103 (7) | 0 (0) | 2 (0.3) |
| Obese BMI | |||
| No | 1084 (68) | 446 (67) | 500 (66) |
| Yes | 500 (32) | 223 (33) | 256 (34) |
| Overweight BMI | |||
| No | 1079 (68) | 444 (66) | 508 (67) |
| Yes | 505 (32) | 225 (34) | 248 (33) |
| Graft typea | |||
| Bone marrow | 505 (32) | 161 (24) | 260 (34) |
| Peripheral blood | 1079 (68) | 508 (76) | 496 (66) |
| Conditioning intensity | |||
| Myeloablative | 1079 (68) | 453 (68) | 549 (73) |
| Reduced intensity | 505 (32) | 216 (32) | 207 (27) |
| Total body irradiation | |||
| No | 1021 (64) | 472 (71) | 489 (65) |
| Yes | 563 (36) | 197 (29) | 267 (35) |
| Disease status at diagnosis | |||
| Early | 1107 (70) | 428 (64) | 486 (64) |
| Advanced | 477 (30) | 241 (36) | 270 (36) |
| Recipient CMV status | |||
| Negative | 716 (45) | 306 (46) | 361 (48) |
| Positive | 868 (55) | 363 (54) | 395 (52) |
| Donor CMV status | |||
| Negative | 1080 (68) | 472 (71) | 513 (68) |
| Positive | 504 (32) | 197 (29) | 243 (32) |
| Diagnosed with AMLa | |||
| No | 337 (21) | 192 (29) | 208 (28) |
| Yes | 1247 (79) | 477 (71) | 548 (72) |
| Diagnosed with MDS | |||
| No | 1247 (79) | 477 (71) | 548 (72) |
| Yes | 337 (21) | 192 (29) | 208 (28) |
| Primary cause of death | |||
| aGVHD | 95 (0.06) | 56 (0.08) | 49 (0.06) |
| Infection | 86 (0.05) | 25 (0.04) | 36 (0.05) |
| Category/characteristics . | Cohort 1 (N = 1584), n (%) . | Cohort 2 (N = 669), n (%) . | Cohort with sST2 level measurements (N = 756), n (%) . |
|---|---|---|---|
| Recipient age, y | |||
| ≥40 | 1132 (71) | 481 (72) | 532 (70) |
| <40 | 452 (29) | 188 (28) | 224 (30) |
| Donor age, ya | |||
| ≥30 | 963 (61) | 347 (52) | 392 (52) |
| <30 | 621 (39) | 322 (48) | 364 (48) |
| Recipient sex | |||
| Female | 723 (46) | 303 (45) | 340 (45) |
| Male | 861 (54) | 366 (55) | 416 (55) |
| Donor sex | |||
| Female | 498 (31) | 181 (27) | 198 (26) |
| Male | 1086 (69) | 488 (73) | 558 (74) |
| Blood mismatch | |||
| No type mismatch | 674 (43) | 293 (44) | 332 (44) |
| Donor–recipient mismatch | 910 (57) | 376 (56) | 424 (56) |
| Anti-thymocyte globulin/alemtuzumab prophylaxis* | |||
| No | 1074 (68) | 396 (59) | 477 (63) |
| Yes | 407 (26) | 273 (41) | 277 (37) |
| Missing | 103 (7) | 0 (0) | 2 (0.3) |
| Obese BMI | |||
| No | 1084 (68) | 446 (67) | 500 (66) |
| Yes | 500 (32) | 223 (33) | 256 (34) |
| Overweight BMI | |||
| No | 1079 (68) | 444 (66) | 508 (67) |
| Yes | 505 (32) | 225 (34) | 248 (33) |
| Graft typea | |||
| Bone marrow | 505 (32) | 161 (24) | 260 (34) |
| Peripheral blood | 1079 (68) | 508 (76) | 496 (66) |
| Conditioning intensity | |||
| Myeloablative | 1079 (68) | 453 (68) | 549 (73) |
| Reduced intensity | 505 (32) | 216 (32) | 207 (27) |
| Total body irradiation | |||
| No | 1021 (64) | 472 (71) | 489 (65) |
| Yes | 563 (36) | 197 (29) | 267 (35) |
| Disease status at diagnosis | |||
| Early | 1107 (70) | 428 (64) | 486 (64) |
| Advanced | 477 (30) | 241 (36) | 270 (36) |
| Recipient CMV status | |||
| Negative | 716 (45) | 306 (46) | 361 (48) |
| Positive | 868 (55) | 363 (54) | 395 (52) |
| Donor CMV status | |||
| Negative | 1080 (68) | 472 (71) | 513 (68) |
| Positive | 504 (32) | 197 (29) | 243 (32) |
| Diagnosed with AMLa | |||
| No | 337 (21) | 192 (29) | 208 (28) |
| Yes | 1247 (79) | 477 (71) | 548 (72) |
| Diagnosed with MDS | |||
| No | 1247 (79) | 477 (71) | 548 (72) |
| Yes | 337 (21) | 192 (29) | 208 (28) |
| Primary cause of death | |||
| aGVHD | 95 (0.06) | 56 (0.08) | 49 (0.06) |
| Infection | 86 (0.05) | 25 (0.04) | 36 (0.05) |
Significant difference between cohorts 1 and 2 (P < .001).